ロード中...
Escalation strategies for combination therapy Phase I trials
Phase I clinical trials aim to identify a maximum tolerated dose (MTD), the highest possible dose that does not cause an unacceptable amount of toxicity in the patients. In trials of combination therapies, however, many different dose combinations may have a similar probability of causing a dose-lim...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Ltd
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3573644/ https://ncbi.nlm.nih.gov/pubmed/22411472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pst.1497 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|